Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-29

Clinical Trial Update: A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study to prevent rash in people starting alpelisib for breast cancer was terminated. Results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Piqray (alpelisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-08-29